NCB-02 (standardized Curcumin preparation) protects dinitrochlorobenzene-induced colitis through down-regulation of NFκ-B and iNOS

Abstract

at a dose of 100 mg/kg b.wt. inhibited the DNCB-induced overexpression of NFκ-B and iNOS in the colon. CONCLUSION:Curcumin treatment ameliorates colonic damage in DNCB-induced colitic rats, an effect associated with an improvement in intestinal oxidative stress and downregulation of colonic NFκ-B and iNOS expression. INTRODUCTIONInflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis (UC), is a chronic and relapsing inflammatory disease caused by the inflammation and sores in the lining of large intestine and characterized clinically by recurrent episodes of bloody diarrhea, cramping, abdominal pain and histologically by mucosal inflammation and injury [1] . Conventional therapy for UC includes sulfasalazine and other 5-aminosalicylic acid (5-ASA) type of compounds, and in more persistent and/ or severe cases, oral, rectal and parenteral corticosteroids and immunosuppressants are administered [2] . All of these have significant toxicities and are partly or completely ineffective in significant numbers of patients [3] . Several agents used in the management of IBD, such as corticosteroids, sulfasalazine and 5-ASA, have documented regulation of Nuclear Factor K appa-B (NF κ-B) function [2] . Given the importance of inflammatory cell activation involved in the development of IBD, there is a need for a treatment modality against IBD that can block the inflammatory processes. There is substantial evidence for the involvement of oxidative stress and profound alterations in the biosynthesis of the labile free Abstract AIM: To evaluate the efficacy and mechanism of action of NCB-02, a standardized Curcumin preparation, against 2, 4-dinitrochlorobenzene (DNCB)-induced ulcerative colitis in rats.

Curcumin: an orally bioavailable blocker of TNF and other pro‐inflammatory biomarkers

“…Firstly, epidemiological studies indicate that turmeric (which contains 2-8% curcuminoids) may contribute to the lower incidence of cancer, especially large-bowel cancers in Indians (Mohandas and Desai, 1999;Sinha et al, 2003). Secondly, curcumin, when administered orally in the diet, prevented trinitrobenzene sulfonic acid (TNBS)-or dinitrobenzene sulfonic acid (DNBS)-induced colitis in mice (Sugimoto et al, 2002;Salh et al, 2003;Venkataranganna et al, 2007;Ung et al, 2010). Thirdly, curcumin improves both the wasting and histopathological signs of colonic inflammation.…”

“…• Protected against DNCB-induced colitis through down-regulation of MPO, ALP, LPO, NF-kB and iNOS (Venkataranganna et al, 2007).…”

Limited effects of dietary curcumin on Th-1 driven colitis in IL-10 deficient mice suggest an IL-10-dependent mechanism of protection

“…These effects have been reported in many cell types, including intestinal epithelial cells (20), mac-rophages, dendritic cells, B cells, and T cells (17). The potential usefulness of curcumin in the treatment of IBD was suggested by studies in chemically induced rodent models of colitis (19,35,46,48,49,51,52). Curcumin has also been demonstrated as an effective agent in maintenance therapy of UC (15), and encouraging, though not conclusive, data were obtained in a small clinical trial in CD patients (16).…”

Nutritional support and dietary interventions for patients with ulcerative colitis: current insights

“…Although the mechanism of action of curcumin is not fully defined, 76 it is suggested to exert inhibitory influence on nuclear factor kappa beta and inducible nitric oxide synthase, 79,80 thereby modulating the inflammatory cascade. The studies detailed show promise for curcumin as a dietary therapy for patients with UC, and curcumin was reported to be well tolerated in the studies.…”